Survey
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
Attachment 1: Product information for AusPAR Remicade Janssen-Cilag Pty Ltd PM-201100196-3-1 Final 17 December 2012. This Product Information was approved at the time this AusPAR was published. Paediatric Malignancy Post-marketing cases of malignancies, some fatal, have been reported among children, adolescents and young adults (up to 22 years of age) who received TNF-blocking agents (initiation of therapy ⤠18 years of age), including REMICADE, to treat Juvenile Idiopathic Arthritis (JIA), Crohnâs disease or other conditions. Approximately half the reports were lymphomas (Hodgkinâs and non-Hodgkinâs lymphoma). The other cases represented a variety of different malignancies and included malignancies that are not usually observed in children and adolescents. Most of the patients were receiving concomitant immunosuppressants, such as methotrexate, azathioprine or 6-mercaptopurine. The role of TNF blockers in the development of malignancies in children and adolescents remains unclear. Hepatosplenic T-cell lymphomas Rare postmarketing cases of hepatosplenic T-cell lymphoma have been reported in patients treated with TNF-blocking agents including REMICADE. This rare type of T-cell lymphoma has a very aggressive disease course and is usually fatal. All REMICADE cases have occurred in patients with Crohn's disease or ulcerative colitis and the majority were reported in adolescent or young adult males. All of these patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with or immediately prior to REMICADE. *It is uncertain whether the occurrence of the HSTCL is related to REMICADE or REMICADE in combination with these other immunosuppressants. When treating patients with inflammatory bowel disease, particularly in adolescents and young adults, consideration of whether to use REMICADE alone or in combination with other immunosuppressants should take into account a possibility that there is a higher risk of HSTCL with combination therapy versus an observed increased risk of immunogenicity and hypersensitivity reactions with REMICADE monotherapy from the clinical trial data. Leukaemia Cases of acute and chronic leukaemia have been reported with post-marketing TNF-blocker use in rheumatoid arthritis and other indications. Even in the absence of TNF blocker therapy, patients with rheumatoid arthritis may be at a higher risk (approximately 2-fold) than the general population for the development of leukaemia. *Colon Carcinoma/Dysplasia All patients with ulcerative colitis who are at increased risk for dysplasia or colon carcinoma (for example, patients with long-standing ulcerative colitis or primary sclerosing cholangitis), or who had a prior history of dysplasia or colon carcinoma should be screened for dysplasia at regular intervals before therapy and throughout their disease course. This evaluation should include colonoscopy and biopsies per local recommendations. With current data it is not known if REMICADE treatment influences the risk for developing dysplasia or colon cancer (see ADVERSE EFFECTS section). Since the possibility of increased risk of cancer development in patients with newly diagnosed dysplasia treated with REMICADE is not established, the risk and benefits to the individual patients must be carefully reviewed and consideration should be given to discontinuation of therapy. Auto-immune processes The relative deficiency of TNFï¡ caused by anti-TNF therapy may result in the initiation of an autoimmune process in a subgroup of genetically susceptible patients. If drug-induced lupus is suspected, patients being treated with REMICADE should have regular measurements of Antinuclear antibodies (ANA) and double-stranded DNA (dsDNA) antibodies. If a patient develops symptoms suggestive of a lupus-like syndrome following treatment with REMICADE REMICADE (120507) API Page 21